RESEARCH FOCUS: Immuno-oncology


About NKTR-255

NKTR-255 is an IL-15 receptor agonist designed to engage the IL-15 pathway to stimulate and expand natural killer (NK) cells and promote the survival and expansion of central memory CD8+ T cells without inducing suppressive regulatory T cells. Through optimal engagement of the IL-15Rα/IL-2Rγ receptor complex, NKTR-255 enhances formation of long-term immunological memory which may lead to sustained anti-tumor immune response. Native rhIL-15 is rapidly cleared from the body and must be administered frequently and in high doses limiting its utility due to toxicity. NKTR-255 is designed with IL-15 receptor alpha specificity to optimize biological activity and is uniquely engineered to provide optimal exposure and an improved safety profile.

In oncology, NKTR-255 is currently being evaluated in preclinical studies in combination with targeted antibody therapies in lymphoma and multiple myeloma. Through a collaboration with Fred Hutchinson Cancer Center, NKTR-255 is being evaluated in combination with CAR-T therapy in preclinical studies. NKTR-255 will also be explored in combination with anti-retroviral and immune modulator therapies through a research collaboration with Gilead.

4th Congress of European Hematology Association (EHA)

AACR 2019

2018 ASH 60th Annual Meeting

SITC 2018

2018 American Conference on Pharmacometrics (ACoP), San Diego, CA

CHI 3rd Annual NK Cell-Based Cancer Immunotherapy Conference, Boston, MA

CHI 2nd Annual Emerging Immuno-Oncology Targets Conference, Boston, MA

Society for Immunotherapy in Cancer (SITC) 32nd Annual Meeting, National Harbor, MD

2017 American Association for Cancer Research (AACR) Annual Meeting

2016 SITC Annual Meeting